HRP20041193A2 - Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release - Google Patents

Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release

Info

Publication number
HRP20041193A2
HRP20041193A2 HR20041193A HRP20041193A HRP20041193A2 HR P20041193 A2 HRP20041193 A2 HR P20041193A2 HR 20041193 A HR20041193 A HR 20041193A HR P20041193 A HRP20041193 A HR P20041193A HR P20041193 A2 HRP20041193 A2 HR P20041193A2
Authority
HR
Croatia
Prior art keywords
pharmaceutical composition
composition containing
active substance
substance release
controlled active
Prior art date
Application number
HR20041193A
Other languages
English (en)
Inventor
Franke Hanshermann
Lennartz Peter
Original Assignee
Desitin Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10224170A external-priority patent/DE10224170A1/de
Priority claimed from DE10250566A external-priority patent/DE10250566A1/de
Application filed by Desitin Arzneimittel Gmbh filed Critical Desitin Arzneimittel Gmbh
Publication of HRP20041193A2 publication Critical patent/HRP20041193A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20041193A 2002-05-31 2004-12-16 Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release HRP20041193A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10224170A DE10224170A1 (de) 2002-05-31 2002-05-31 Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
DE10224177 2002-05-31
DE10250566A DE10250566A1 (de) 2002-05-31 2002-10-30 Pharmazeutische Zusammensetzung, enthaltend Oxcarbazepin mit verzögerter Wirkstofffreisetzung
PCT/EP2003/005116 WO2003101430A1 (de) 2002-05-31 2003-05-15 Pharmazeutische zusammensetzung, enthaltend oxcarbazepin mit kontrollierter wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
HRP20041193A2 true HRP20041193A2 (en) 2005-06-30

Family

ID=29715723

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20041193A HRP20041193A2 (en) 2002-05-31 2004-12-16 Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release

Country Status (11)

Country Link
US (2) US20040185095A1 (pt)
EP (1) EP1509207B1 (pt)
JP (1) JP2005528429A (pt)
AU (1) AU2003240654A1 (pt)
BR (1) BR0311327A (pt)
CA (1) CA2485932A1 (pt)
HR (1) HRP20041193A2 (pt)
MX (1) MXPA04011801A (pt)
NO (1) NO20045385L (pt)
PL (1) PL374778A1 (pt)
WO (1) WO2003101430A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL374778A1 (en) * 2002-05-31 2005-10-31 Desitin Arzneimittel Gmbh Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
AR048672A1 (es) * 2004-03-22 2006-05-17 Novartis Ag Tabletas de desintegracion que comprenden licarbazepina
AR048318A1 (es) * 2004-03-22 2006-04-19 Novartis Ag Formulaciones de matriz orales que comprenden licarbazepina
US20090196919A1 (en) * 2004-10-25 2009-08-06 Ajay Singla Oxcarbazepine dosage forms
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
JP2008540346A (ja) * 2006-01-31 2008-11-20 テバ ファーマシューティカル インダストリーズ リミティド オキシカルバゼピンの医薬製剤及びその調製方法
US20070248684A1 (en) * 2006-01-31 2007-10-25 Sigal Blau Pharmaceutical formulations of oxcarbazepine and methods for its preparation
WO2007089247A1 (en) * 2006-01-31 2007-08-09 Teva Pharmaceutical Industries Ltd. Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
WO2007122635A2 (en) 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
EP2026815B1 (en) 2006-04-26 2011-01-26 Supernus Pharmaceuticals, Inc. Controlled released preparations of oxcarbazepine having sigmoidal release profile
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
EP2077822B1 (en) * 2006-09-27 2018-04-25 Medley S.A. Indústria Farmacêutica Oxcarbazepine-containing oral formulation and a process to obtain the same
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
ITMI20071502A1 (it) * 2007-07-25 2009-01-26 Archimica Srl Procedimento per la preparazione di formulazioni solide a rilascio controllato contenenti oxcarbazepina e formulazioni ottenibili con tale procedimento
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
WO2015063670A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Solid oral modified-release composition comprising oxcarbazepine or a pharmaceutically acceptable salt thereof
AU2018300080A1 (en) 2017-07-11 2020-02-13 Sustained Nano Systems Llc Hypercompressed pharmaceutical formulations
CN111032054A (zh) 2017-07-11 2020-04-17 持续纳米***有限责任公司 超压缩聚合物剂型的辐射灭菌

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US22056A (en) * 1858-11-16 Infant s cradle
JP2684463B2 (ja) * 1991-04-19 1997-12-03 富士写真フイルム株式会社 写真要素
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
US5472714A (en) * 1993-09-08 1995-12-05 Ciba-Geigy Corporation Double-layered oxcarbazepine tablets
US5696782A (en) * 1995-05-19 1997-12-09 Imra America, Inc. High power fiber chirped pulse amplification systems based on cladding pumped rare-earth doped fibers
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
US20020022056A1 (en) * 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
PL374778A1 (en) * 2002-05-31 2005-10-31 Desitin Arzneimittel Gmbh Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release

Also Published As

Publication number Publication date
EP1509207B1 (de) 2009-04-29
NO20045385L (no) 2004-12-09
WO2003101430A1 (de) 2003-12-11
AU2003240654A1 (en) 2003-12-19
EP1509207A1 (de) 2005-03-02
US20040142033A1 (en) 2004-07-22
JP2005528429A (ja) 2005-09-22
CA2485932A1 (en) 2003-12-11
US20040185095A1 (en) 2004-09-23
PL374778A1 (en) 2005-10-31
MXPA04011801A (es) 2005-09-12
BR0311327A (pt) 2005-02-22

Similar Documents

Publication Publication Date Title
HRP20041193A2 (en) Pharmaceutical composition containing oxcarbazepine and having a controlled active substance release
IL163866A0 (en) 8-Azaprostaglandin derivative compounds and drugs containing the compounds s active ingredient
HUP0301242A3 (en) Controlled release drug dosage form
HK1040995A1 (zh) 二氧喹啉化合物及其醫藥用途
HUP0203556A3 (en) Pharmaceutical compositions containing oxcarbazepine and their use
IL145581A0 (en) A modified release pharmaceutical composition comprising amoxycillin
IL209444A0 (en) O-desmethyl-venlafaxine succinate salts and pharmaceutical compositions containing them
HUP0203378A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
IL164699A0 (en) Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient
HUP0203939A3 (en) Pharmaceutical compounds and compositions containing them and their use
HUP0402236A3 (en) Heterocyclic compounds pharmaceutical compounds containing thereof and use thereof
IL148489A0 (en) Quinazoline compounds and pharmaceutical compositions containing them
HUP0200714A3 (en) Pharmaceutical compounds, pharmaceutical compositions containing them and their use
IL161940A0 (en) Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient
EP1408907A4 (en) DOSAGE AND PACKAGING OF CONTROLLED RELEASE DRUGS
AU1724301A (en) Hydrogel-driven layered drug dosage form
EG24479A (en) Modified release pharmaceutical formulation
IL146632A0 (en) Pharmaceutical tablets
HUP0202255A3 (en) Crystalline 1-methylcarbapenem compounds and pharmaceutical compositions containing them
HUP0000137A3 (en) Controller-release pharmaceutical composition containing anangetics
HUP0204069A3 (en) Novel processes for making- and a new crystalline form of- leflunomide and pharmaceutical composition containing it
HUP0203121A3 (en) Pharmaceutical composition containing substituted benzimidazoles and its use
AU2002218502A1 (en) Lactam compounds and medicinal use thereof
HUP0203383A3 (en) Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
AU2001280830A1 (en) Paroxetine tablets and capsules

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20060420

Year of fee payment: 4

OBST Application withdrawn